17. 多系統萎縮症 Multiple system atrophy Clinical trials / Disease details

臨床試験数 : 118 / 薬物数 : 163 - (DrugBank : 49) / 標的遺伝子数 : 61 - 標的パスウェイ数 : 112

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT03753763 (ClinicalTrials.gov)	October 29, 2019	19/11/2018	Safinamide for Multiple System Atrophy (MSA)	12-weeks, Multicentre, Randomized, Double-blind, Placebo-controlled, Exploratory, Pilot Study to Evaluate the Safety and Efficacy of Safinamide 200 mg OD, as add-on Therapy, in Patients With Possible or Probable Parkinsonian Variant of MSA	Multiple System Atrophy	Drug: Safinamide Methanesulfonate;Drug: Safinamide Methanesulfonate matching placebo	Zambon SpA	NULL	Completed	30 Years	80 Years	All	49	Phase 2	Italy;Spain
2	EUCTR2018-004145-16-ES (EUCTR)	24/07/2019	11/06/2019	A study evaluating the safety and efficacy of safinamide for patients with Multiple System Atrophy	A 12-weeks, multicentre, randomized, double-blind, placebo-controlled, exploratory, pilot study to evaluate the safety and efficacy of safinamide 200 mg once daily, as add-on therapy, in patients with possible or probable parkinsonian variant of multiple system atrophy. - Safinamide for Multiple System Atrophy	Parkinsonian variant of Multiple System Atrophy MedDRA version: 20.0;Level: PT;Classification code 10064060;Term: Multiple system atrophy;System Organ Class: 10029205 - Nervous system disorders ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10]	Trade Name: Xadago INN or Proposed INN: safinamide methanesulfonate Other descriptive name: SAFINAMIDE	Zambon SpA	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	48	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no	Spain